適體市場規模、佔有率、成長分析（按類型、應用和地區）-產業預測，2024-2031

2022年全球適配體市場規模將為1.55億美元，從2023年的1.8259億美元成長到2031年的6.7708億美元，預計在預測期內（2024-2031年）將以17.80的複合年成長率。

適體因其在生產、精製和標靶藥物遞送方面的最新進展而引起了研究人員的極大興趣。與傳統抗體相比，這些優點包括分子尺寸較小、免疫抗原性較低、製造成本較低、副作用較少。這些特性可能有助於創新適配體的開發，並成為市場開拓的驅動力。儘管進行了廣泛的研究，但目前還沒有針對各種基因突變引起的感染疾病的高效治療方法。然而，基於 SELEX 技術的診斷套件和檢測方法已顯示出生產高親和性中和劑的前景。這一市場開拓預計將透過採用新的診斷試劑套件帶來市場成長。適配體是利用DNA適配體技術開發的第二代診斷工具。這些套件具有成本效益，是化學合成的，並且在診斷中越來越受歡迎。例如，2022 年 3 月，Soma Logic 宣布將採用 SomaScan Assay 分析 30,000 個樣本中的 2.1 億個蛋白質測量結果，用於歐洲癌症與營養前瞻性調查 (EPIC) 研究。這種方法旨在增強疾病預測，特別是癌症，並支持市場擴張。基於適體的診斷解決方案因其尺寸小、特異性高、選擇性良好以及在細胞層面檢測疾病方面的有效性而受到診斷和病理實驗室的青睞。根據英國癌症研究中心估計，到 2040 年，預計將有約 2,750 萬人被診斷出患有癌症，這增加了對先進診斷技術的需求。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 次要/一級資訊來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 技術分析
• 價值鏈分析
• 專利分析

適體市場：依類型

• 市場概況
• DNA適體
• XNA適體
• RNA適體

適體市場：依技術分類

• 市場概況
• SELEX
• 其他技術

適體市場：依應用分類

• 市場概況
• 治療藥物開發
• 研究與開發
• 診斷
• 其他用途

適體市場：依最終用戶分類

• 市場概況
• 製藥和生物技術公司
• 學術/政府研究院
• 藥品委外研發機構
• 其他最終用戶

適體市場規模：按地區分類

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Aptamer Group（UK）
• Raptamer Discovery Group（US）
• omalogic, Inc.（US）
• Aptamer Sciences, Inc.（US）
• Aptagen, LLC（US）
• Maravai Lifesciences（US）
• Kaneka Corporation（Japan）
• Neoventures Biotechnology Inc.（Canada）
• Aptus Biotech（Spain）
• Base Pair Biotechnologies（US）
• Amsbio（UK）
• Novaptech（France）
• Bio-Techne（US）
• Aptitude Medical Systems（US）
• Raybiotech, Inc.（US）
• Alpha Diagnostic International, Inc.（US）
• Creative Biolabs（US）
• Creative Biogene（US）
• Vivonics Inc.（US）
• Iba Lifesciences GmbH（Germany）
• Aptabharat Innovations Pvt. Ltd（India）
• Profacgen（US）
• Mediven（Germany）
• Pure Biologics SA（Poland）
• Oak Biosciences, Inc.（US）

Global Aptamers Market size was valued at USD 155 million in 2022 and is poised to grow from USD 182.59 million in 2023 to USD 677.08 million by 2031, growing at a CAGR of 17.80% during the forecast period (2024-2031).

Aptamers have gained significant interest from researchers due to their distinct advantages in recent advancements related to production, purification, and targeted drug delivery. These benefits include their small molecular size, low immunogenicity, reduced manufacturing costs, and fewer side effects compared to traditional antibodies. These attributes contribute to the potential development of innovative aptamers, which may drive market growth. Despite extensive research, there are currently no highly effective treatments for infections due to various genetic variations. However, SELEX technology-based diagnostic kits and assays have shown promise in generating high-affinity neutralizers. This development is expected to stimulate market growth with the introduction of new diagnostic kits. Aptamers represent a second-generation diagnostic tool developed using DNA aptamer technology. These kits are cost-effective, chemically synthesized, and increasingly popular in diagnostics. For instance, in March 2022, Soma Logic announced that it was employing the SomaScan Assay to analyze 210 million protein measurements from 30,000 samples for the European Prospective Investigation into Cancer and Nutrition (EPIC) study. This approach aims to enhance disease prediction, particularly cancer, thereby supporting market expansion. Aptamer-based diagnostic solutions are favored by diagnostic and pathology labs due to their small size, high specificity, selectivity, and effectiveness in cellular-level disease detection. According to Cancer Research UK, it is estimated that around 27.5 million people will receive a cancer diagnosis by 2040, underscoring the growing demand for advanced diagnostic technologies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Aptamers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Aptamers Market Segmental Analysis

Global Aptamers Market is segmented by Type, Technology, Application, End User, and region. Based on Type, the market is segmented into DNA Aptamers, XNA Aptamers, and RNA Aptamers. Based on Technology, the market is segmented into SELEX, Other Technologies. Based on Application, the market is segmented into Therapeutics Development, Research & Development, Diagnostics, Other Applications. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, Contract Research Organizations, Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Aptamers Market

The increasing demand for personalized medicine is driving the growth of the global aptamers market. Aptamers, with their ability to bind specifically to target molecules such as proteins, peptides, and small compounds, are becoming essential in the development of targeted therapies and precision medicine. Their high specificity, low immunogenicity, and customizable nature make them ideal for personalized treatment strategies. Additionally, aptamers offer significant advantages over traditional antibodies, such as easier synthesis, cost-effective production, and enhanced binding affinity, making them highly attractive for diagnostic, therapeutic, and research applications.

Restraints in the Global Aptamers Market

Intellectual property (IP) issues pose significant challenges to the growth of the aptamers market. Patent rights and licensing agreements for aptamers and their associated technologies can restrict the commercialization potential for specific applications or targets. The complex IP landscape related to aptamer-based technologies can create legal uncertainties and obstacles for market participants. These IP complexities may impede market progress by making it difficult for companies to navigate patent claims and secure necessary licenses. Consequently, such legal barriers can limit the opportunities for innovation and expansion within the aptamers sector.

Market Trends of the Global Aptamers Market

SELEX (Systematic Evolution of Ligands by Exponential Enrichment) remains the leading technique for selecting aptamers. To boost efficiency, lower costs, and enhance the quality of aptamers, there is an increasing emphasis on optimizing and automating the SELEX process. Recent advancements in high-throughput screening, microfluidics, and robotics are being utilized to refine the aptamer development workflow, making it more efficient and scalable. These technological improvements aim to streamline the SELEX process, facilitating better and faster production of aptamers. By integrating these innovations, the process becomes more accessible and adaptable, addressing previous limitations and expanding the potential for aptamer applications.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Technology Analysis
• Value Chain Analysis
• Patent Analysis

Aptamers Market, By Type

• Market Overview
• DNA Aptamers
• XNA Aptamers
• RNA Aptamers

Aptamers Market, By Technology

• Market Overview
• SELEX
• Other Technologies

Aptamers Market, By Application

• Market Overview
• Therapeutics Development
• Research & Development
• Diagnostics
• Other Applications

Aptamers Market, By End User

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Academic & Government Research Institutes
• Contract Research Organizations
• Other End Users

Aptamers Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Aptamer Group (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Raptamer Discovery Group (US)
  • S Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• omalogic, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptamer Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptagen, LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Maravai Lifesciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kaneka Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neoventures Biotechnology Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptus Biotech (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Base Pair Biotechnologies (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amsbio (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novaptech (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptitude Medical Systems (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Raybiotech, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alpha Diagnostic International, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Biolabs (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Biogene (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vivonics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iba Lifesciences GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptabharat Innovations Pvt. Ltd (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Profacgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mediven (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pure Biologics SA (Poland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oak Biosciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments